IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with […]

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

Q1 earnings show this Dividend King still looks built for the long term.

In recent weeks, AbbVie reported first-quarter 2026 revenue of US$15,002 million, while also securing new Canadian formulary listings and reimbursement progress for SKYRIZI in ulcerative colitis alongside fresh clinical and regulatory updates for SKYRIZI and RINVOQ across inflammatory and autoimmune diseases. Together with an ongoing dividend record and advances in areas such as immunology, gastroenterology and oncology partnerships, these developments highlight how AbbVie is leaning on its...

They have combined for 118 years of consecutive dividend increases.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Clinical Trials Arena rounds up the key readouts from the 2026 Digestive Disease Week conference held in Chicago.

These stocks check off multiple boxes for income investors.